{"links":{"html":"https://www.erudio.com/reports/immagine-3-nct06413498","json":"https://www.erudio.com/reports/immagine-3-nct06413498.json","markdown":"https://www.erudio.com/reports/immagine-3-nct06413498.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"immagine-3-06413498"}},"request":"https://www.erudio.com/contact?report=immagine-3-06413498"},"offer":{"cited_commentary_sources":19,"verified_hcp_statements":307,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI. For scientific and insight use inside the organization, not for promotional targeting or outreach. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":1950,"identity_verified_people":3,"optional":true,"price_per_verified_person_usd":15,"price_usd":45,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"immagine-3-nct06413498"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=immagine-3-06413498","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/immagine-3-nct06413498","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"deep","size_rule":"Deep: 301+ verified statements","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-19T02:39:07.024772Z","notify_subscribers":false,"status":"corrected","summary":"Report description rewritten to say where clinicians' views stand, not only what they discuss"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":0},"aspects":[{"claim_count":12,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":6,"title":"Primary endpoint: Progression-Free Survival (PFS)"},{"claim_count":9,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":5,"title":"Primary endpoint: Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 Months"},{"claim_count":11,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":6,"title":"Secondary endpoints"},{"claim_count":17,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":10,"title":"Population and setting"},{"claim_count":15,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":11,"title":"The comparison"},{"claim_count":36,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":10,"title":"Safety and tolerability"},{"claim_count":10,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":9,"title":"Design and conduct"},{"claim_count":29,"coverage":"discussed","id":"A1","source_count":7,"title":"CAR-T versus bispecific sequencing and prior target exposure"},{"claim_count":25,"coverage":"discussed","id":"A2","source_count":7,"title":"Disease tempo, bridging and pre-CAR-T disease control"},{"claim_count":10,"coverage":"discussed","id":"A3","source_count":2,"title":"Functional high risk after contemporary frontline treatment"},{"claim_count":27,"coverage":"discussed","id":"A4","source_count":4,"title":"MRD assay choice, timing and clinical actionability"},{"claim_count":30,"coverage":"discussed","id":"A5","source_count":9,"title":"Manufacturing, outpatient delivery, referral and patient support"},{"claim_count":12,"coverage":"discussed","id":"A6","source_count":5,"title":"Conditional roles for transplantation and conventional therapy"},{"claim_count":18,"coverage":"discussed","id":"A7","source_count":9,"title":"Prospective approval, treatment-line access and positioning"},{"claim_count":26,"coverage":"discussed","id":"A8","source_count":11,"title":"D-domain and BCMA rationale"}],"counts":{"cited_sources":19,"claims_by_expression_type":{"comparison":31,"experience":14,"interpretation":39,"opinion":23,"primary_context":5,"question":15,"restatement":44,"uncertainty":34,"unspecified":102},"claims_by_kind":{"attributed_opinion":5,"interpretation":1,"limitation":2,"source_observation":299},"clinician_statements":25,"evidence_units":122,"findings":12,"people_cited":8,"people_identity_verified":3,"people_total":10,"screened_sources":21,"verified_claims":307},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":23,"claims_by_group":{"comparisons":3,"experience":2,"questions":3,"restated":14,"views":1},"has_counterview":true,"limitations":4,"links":{"context":6,"support":29},"ma_question":true,"named_voices":7,"passages":22,"sources":15,"sources_by_kind":{"commentary":4,"media":11}},"title":"Randomized evidence must resolve the comparison—not cross-trial resemblance"},{"id":"F2","structure":{"claims":25,"claims_by_group":{"comparisons":2,"experience":0,"questions":3,"restated":16,"views":4},"has_counterview":false,"limitations":2,"links":{"context":12,"support":43},"ma_question":true,"named_voices":5,"passages":19,"sources":8,"sources_by_kind":{"commentary":1,"media":7}},"title":"Favorable neurological signals remain provisional and coexist with serious harms"},{"id":"F3","structure":{"claims":37,"claims_by_group":{"comparisons":5,"experience":1,"questions":13,"restated":4,"views":14},"has_counterview":true,"limitations":4,"links":{"context":3,"support":43},"ma_question":true,"named_voices":1,"passages":24,"sources":7,"sources_by_kind":{"media":7}},"title":"CAR-T-first preferences depend on eligibility, treatment availability and prior target exposure"},{"id":"F4","structure":{"claims":37,"claims_by_group":{"comparisons":4,"experience":5,"questions":9,"restated":8,"views":11},"has_counterview":true,"limitations":3,"links":{"context":5,"support":47},"ma_question":true,"named_voices":1,"passages":27,"sources":7,"sources_by_kind":{"media":7}},"title":"Bridging must control disease without losing the opportunity to deliver CAR-T"},{"id":"F5","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":6,"views":2},"has_counterview":false,"limitations":3,"links":{"context":1,"support":12},"ma_question":true,"named_voices":2,"passages":4,"sources":2,"sources_by_kind":{"media":2}},"title":"Costa proposes reconsidering functional high risk after modern frontline treatment"},{"id":"F6","structure":{"claims":43,"claims_by_group":{"comparisons":3,"experience":1,"questions":6,"restated":26,"views":7},"has_counterview":false,"limitations":3,"links":{"context":14,"support":85},"ma_question":true,"named_voices":5,"passages":24,"sources":11,"sources_by_kind":{"media":11}},"title":"Rapid, deep responses motivate enthusiasm, but durability remains an open question"},{"id":"F7","structure":{"claims":28,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":14,"views":10},"has_counterview":true,"limitations":2,"links":{"context":9,"support":43},"ma_question":true,"named_voices":4,"passages":20,"sources":11,"sources_by_kind":{"commentary":1,"media":10}},"title":"D-domain explanations offer a rationale, not proof of a clinical safety advantage"},{"id":"F8","structure":{"claims":32,"claims_by_group":{"comparisons":3,"experience":0,"questions":4,"restated":19,"views":6},"has_counterview":true,"limitations":3,"links":{"context":4,"support":41},"ma_question":true,"named_voices":1,"passages":23,"sources":5,"sources_by_kind":{"media":5}},"title":"MRD is valued, but timing, assay logistics and actionability constrain its interpretation"},{"id":"F9","structure":{"claims":32,"claims_by_group":{"comparisons":1,"experience":3,"questions":1,"restated":24,"views":3},"has_counterview":true,"limitations":3,"links":{"context":11,"support":47},"ma_question":true,"named_voices":3,"passages":30,"sources":9,"sources_by_kind":{"commentary":2,"media":7}},"title":"Access requires manufacturing, referral capacity and practical support—not approval alone"},{"id":"F10","structure":{"claims":13,"claims_by_group":{"comparisons":3,"experience":3,"questions":2,"restated":4,"views":1},"has_counterview":true,"limitations":3,"links":{"context":3,"support":18},"ma_question":true,"named_voices":1,"passages":8,"sources":3,"sources_by_kind":{"media":3}},"title":"Class-wide infection and delayed-toxicity concerns remain part of the CAR-T choice"},{"id":"F11","structure":{"claims":13,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":2,"views":7},"has_counterview":true,"limitations":2,"links":{"context":0,"support":14},"ma_question":true,"named_voices":0,"passages":10,"sources":5,"sources_by_kind":{"media":5}},"title":"Transplantation and conventional drugs retain conditional roles rather than disappearing from the sequence"},{"id":"F12","structure":{"claims":19,"claims_by_group":{"comparisons":2,"experience":0,"questions":5,"restated":12,"views":0},"has_counterview":true,"limitations":2,"links":{"context":4,"support":21},"ma_question":true,"named_voices":4,"passages":12,"sources":9,"sources_by_kind":{"commentary":3,"media":6}},"title":"Expected approval does not settle earlier-line access or long-term competitive positioning"}],"medical_affairs_question":"What would constitute persuasive randomized benefit against the standard-care options clinicians actually choose?","sections":{"analysis":[{"id":"section-1","level":2,"title":"The randomized comparison, not resemblance to another CAR-T trial, is the unresolved test"},{"id":"section-2","level":2,"title":"Neurological reassurance must remain alongside serious-harm context"},{"id":"section-3","level":2,"title":"CAR-T first is a preference with eligibility, timing and target exceptions"},{"id":"section-4","level":2,"title":"Bridging is a timing decision as well as a disease-control strategy"},{"id":"section-5","level":3,"title":"Collection timing and bridge toxicity qualify bispecific use"},{"id":"section-6","level":3,"title":"Carfilzomib interest does not establish an optimal bridge"},{"id":"section-7","level":3,"title":"Extramedullary disease and delivery context change the practical choice"},{"id":"section-8","level":2,"title":"Functional high risk may need a different clock after quadruplets"},{"id":"section-9","level":2,"title":"Response depth drives enthusiasm; durable disease control still needs time"},{"id":"section-10","level":2,"title":"D-domain rationale remains distinct from demonstrated clinical advantage"},{"id":"section-11","level":2,"title":"MRD enthusiasm is qualified by when, how and why it is measured"},{"id":"section-12","level":2,"title":"Manufacturing and outpatient hopes meet local delivery and patient burdens"},{"id":"section-13","level":2,"title":"Infection and delayed complications qualify the favorable safety discussion"},{"id":"section-14","level":2,"title":"Limited routine roles still leave access-dependent and sequencing exceptions"},{"id":"section-15","level":2,"title":"Approval expectations leave labeling and durability unresolved"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":3},{"id":"F6","shared_claims":8},{"id":"F12","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression-Free Survival (PFS)"},{"findings":[{"id":"F6","shared_claims":7},{"id":"F8","shared_claims":2}],"id":"T2","label":"Primary endpoint: Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 Months"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F6","shared_claims":9}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":8}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":13},{"id":"F7","shared_claims":1},{"id":"F9","shared_claims":1},{"id":"F12","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":24},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":2},{"id":"F10","shared_claims":13},{"id":"F11","shared_claims":1},{"id":"F12","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":10}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-19T02:39:07.024772Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-19T03:09:56Z","record_hash":"be37ce8c6244253bac4abaf0e6380d399d180e7cc26ab447a36e14955a82c50e","release_hash":"854c5b50460c4251592b1eecf4c8513aa5fd750db3835cac7af4255166ea5f5e","report_id":"erudio-nct06413498","run_id":"8ae88773-04e3-44a4-a16f-b9a6aa5d26c2","schema_version":"5.0","slug":"immagine-3-06413498","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"iMMagine-3 asks whether anito-cel can improve disease control compared with standard treatment options for patients with relapsed or refractory multiple myeloma. Clinicians in the sources reviewed for this edition describe CAR-T-first sequencing preferences as conditional and question the interpretation of cross-trial comparisons. They welcome response depth while treating neurological safety signals as provisional. Long-term durability, randomized benefit and earlier-line access remain unresolved in their commentary.","meta_description":"21 sources screened · 307 verified statements (25 from speakers with a confirmed clinical role) from 19 sources · 12 findings. Updated Oct 19, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-37597481ca9c24820158-a9c14085"],"id":"F1","paraphrase":"An X thread addressed how differences in eligibility criteria and control treatments should enter comparisons between iMMagine-3 and CARTITUDE-4.","publication_caveats":["The account's clinical role is not stated in the sources reviewed for this edition."],"source_channel":"x_thread","source_date":"2026-10-09","title":"Randomized evidence must resolve the comparison—not cross-trial resemblance"},{"cited_claim_ids":["claim-37597481ca9c24820158-6b6858b2"],"id":"F12","paraphrase":"An X account asked which three-year progression-free survival result would justify considering anito-cel comparable to Carvykti.","publication_caveats":["The account's clinical role is not stated in the sources reviewed for this edition."],"source_channel":"x_thread","source_date":"2026-10-09","title":"Expected approval does not settle earlier-line access or long-term competitive positioning"}]},"publication":{"approved_at":"2026-10-19T03:09:56Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-19T03:30:15Z","summary":"Report description rewritten to say where clinicians' views stand, not only what they discuss"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":21},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 2 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","Out of scope: 4 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.","361 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The commentary comes from 21 sources reviewed for this edition. Repeated presentations and posts may describe the same evidence or speakers; source counts do not measure the number of independent clinicians supporting a view.","Searches emphasized study identifiers and drug-name variants. Unnamed discussions, transcription variants and relevant treatment-decision discussions without a trial reference may be missing. Some discussions centered on other CAR-T products or earlier anito-cel studies were excluded, and some passages were not fully assessed.","Posts predating trial registration were excluded when they did not name the trial. Consequently, this edition may miss earlier views on the same relapsed/refractory treatment question.","No protocol or results publication for NCT06413498 was available among the sources reviewed. Earlier-phase efficacy and safety observations must not be read as results of the randomized Phase 3 trial. No exact anitocabtagene autoleucel label was available to establish its current regulatory status.","Different presentations describe different follow-up periods, evaluable populations and data updates. Response, MRD, outpatient-treatment and safety figures are not pooled or treated as interchangeable. Absence of an observed delayed event does not establish absence of risk.","Bhella called a single-arm study requiring at least three prior lines phase 2 IMAGINE-3. That wording is preserved as her account, not adopted as the design of the registered Phase 3 study. Her description of no serious CRS is not reconciled with Kaur's report of fatal CRS in iMMagine-1.","Two videos rely on existing transcripts, which leaves additional uncertainty about wording and speaker identity. Some passages also leave time units, response-category abbreviations, regimen boundaries or bridging proportions unclear; no unstated correction is assumed. One additional CRS passage does not establish an overall incidence clearly enough to report one.","Some speakers and audience members cannot be identified. The unnamed X account's clinical role is unknown. Noopur Raje and Krina Patel are named in their sources, but independent documentation of their clinical roles is unavailable here. Audience experiences are kept separate from clinician assessments and formal trial outcomes.","Some potentially relevant discussion of worldwide access and alternative in-vivo or dual-target CAR-T approaches is incomplete. Missing prior-treatment details and safety qualifications prevent a complete comparison of those alternatives.","A first-line efficacy and tolerability discussion involving an unidentified treatment is not used as evidence for the relapsed/refractory decision. The answer to the MRD quality-of-life question uses DARA-VRD transplant/non-transplant studies only as context for that exchange, not as RRMM or iMMagine-3 evidence. Other frontline quadruplet examples are likewise not used to imply effects in iMMagine-3.","Approval forecasts, expected decision dates, funding descriptions and local access statements reflect the speaker's time and jurisdiction. They do not establish current approval, availability or a subsequent change in clinical opinion.","Parts of Freeman's own construct explanation and Phase 1 durability discussion, as well as portions of future sequencing, combination-treatment and daratumumab-positioning discussions, are not fully represented. Other speakers' accounts cannot substitute for those views, so this edition may miss additional rationales, qualifications or development questions."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":6,"x_video":0,"youtube":11},"by_evidence_role":{"commentary":19},"count":19,"evidence_window":{"end":"2026-10-09","start":"2024-09-27"},"retrieval_snapshot":"2026-10-18T20:40:57.784028Z","timeline":[{"count":1,"week":"2024-W39"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W11"},{"count":1,"week":"2025-W21"},{"count":1,"week":"2025-W24"},{"count":2,"week":"2025-W27"},{"count":1,"week":"2025-W28"},{"count":3,"week":"2025-W31"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W06"},{"count":1,"week":"2026-W14"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W41"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06413498:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06413498:context","quote_policy":"short_quote_link_out"},{"id":"openfda:c961a1ac-6705-4756-9abc-9d84a6fcb5c8:20260903","quote_policy":"short_quote_link_out"},{"id":"openfda:cf5255cc-91fd-4132-973b-764dba142eae:20241014","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:c58453","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:de251e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1790025508018585687:c44117c8-c5a7-41da-bc15-a20fd883638a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1790057950310011192:ee045ef1-3067-40d2-9abb-bdbf5d46856b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1839782233420263439:6c327517-e88c-4f5f-83e6-10dd4f6dcc4a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866297213057638781:9e19e069-d6ca-4836-a98a-bf0475b2980d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1934291293586551021:7f3fef55-ecb8-4d47-b2b0-3b598a365f70","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1942001843456086314:ffe67f72-da67-4ec5-b177-dd5342f2952c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049575229769588819:8a982fc2-458a-4d35-b73c-c6883d99b0bf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108427529308803402:6abdf436-bec1-4321-8e25-1b6a27eda7e7","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:1c_qr1iiJkw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:2d_fXwFJx_0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:FlxqVg6tQV8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:H5tPhPwJSA8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:KJUTJYZcBMQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:OnPYII1jb-M","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:P8bknPBiqOI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:_keNgqjSD-Y","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:fQMo6k0Az8s","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:o2OYT68YBA0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:zcZqwYclhOA","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":8,"x_video":0,"youtube":11},"by_evidence_role":{"commentary":21},"count":21,"evidence_window":{"end":"2026-10-09","start":"2024-05-13"},"retrieval_snapshot":"2026-10-18T20:40:57.784028Z","timeline":[{"count":2,"week":"2024-W20"},{"count":1,"week":"2024-W39"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W11"},{"count":1,"week":"2025-W21"},{"count":1,"week":"2025-W24"},{"count":2,"week":"2025-W27"},{"count":1,"week":"2025-W28"},{"count":3,"week":"2025-W31"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W06"},{"count":1,"week":"2026-W14"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W41"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: anitocabtagene autoleucel","status":"unmapped"},{"brand_names":["Cytoxan","Frindovyx","Neosar"],"label":"cyclophosphamide","slug":"cyclophosphamide"},{"brand_names":["Fludara","Oforta"],"label":"fludarabine","slug":"fludarabine"},{"brand_names":["Pomalyst"],"label":"pomalidomide","slug":"pomalidomide"},{"brand_names":["Velcade"],"label":"bortezomib","slug":"bortezomib"},{"brand_names":["Decadron","Dexacen-4","Dexone","Hemady","Hexadrol","Taperdex"],"label":"dexamethasone","slug":"dexamethasone"},{"brand_names":["Darzalex"],"label":"daratumumab","slug":"daratumumab"},{"brand_names":["Kyprolis"],"label":"carfilzomib","slug":"carfilzomib"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Multiple myeloma","slug":"multiple-myeloma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"iMMagine-3","aliases":["iMMagine-3","A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma"],"brief_title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","collaborators":["Arcellx, Inc."],"conditions":["Multiple Myeloma"],"enrollment":{"count":452,"type":"ACTUAL"},"interventions":[{"name":"Anitocabtagene Autoleucel","synonyms":["CART-ddBCMA"],"type":"DRUG"},{"name":"Cyclophosphamide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Fludarabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pomalidomide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Bortezomib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Dexamethasone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Daratumumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Carfilzomib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06413498","official_title":"A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-07","type":"ESTIMATED"},"primary_endpoints":[{"description":"PFS is defined as the time from randomization to disease progression per International Myeloma Working Group (IMWG) criteria as determined by independent review committee (IRC), or death due to any cause, whichever occurs first.","measure":"Progression-Free Survival (PFS)","timeFrame":"Up to 4 years"},{"description":"Minimal MRD is defined as the proportion of participants achieving CR/stringent CR (sCR) and MRD-negative status at 9 months. MRD negativity at 9 months is defined as negative MRD value at 9 months (± 3 months) in bone marrow assessment (\\< 1 in 105 nucleated cells per IMWG criteria using NGS) (Kumar 2016). CR/sCR per IMWG criteria is determined by IRC.","measure":"Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 Months","timeFrame":"Up to 9 months"}],"registry_last_updated":"2026-07-29","registry_url":"https://clinicaltrials.gov/study/NCT06413498","short_name":"iMMagine-3","short_name_basis":"registry_acronym","sponsor":"Kite, A Gilead Company","start_date":{"date":"2024-08-23","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"KT-US-679-0788","type":"sponsor_study_id"},{"domain":"European Medicines Agency","id":"2024-511188-26","type":"other"},{"domain":"Japan Registry of Clinical Trials","id":"jRCT2043240170","type":"other"}],"study_type":"INTERVENTIONAL"}}}